https://link.springer.com/article/10.1007/s00125-026-06841-z
Läs nedan dokument som är framtaget i konsensus med internationella diabetesorganisationer,
ADA, EASD, ATTD, IDF Europé m fl,
imponerande och värdefullt dokument, väl genomarbetat inom arbetsgruppen,
förefaller ha haft 10 tal digitala möten förutom heldagar
10 olika frågor finns väl belysta, även etiska frågor liksom hälsoekonomi,
bra struktur med i varje fråga fördjupad uppdatering med därefter de 26 kollegernas konsensus
Open source free pdf
https://link.springer.com/article/10.1007/s00125-026-06841-z
International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes: a nominal group technique process
Consensus Report
26 internationella författare, från Sverige Helena Elding Larsson,
157 referenser
Abstract
Type 1 diabetes is an autoimmune disease that targets and destroys insulin-producing beta cells in the pancreatic islets.
The incidence of type 1 diabetes is rising globally. At the clinical diagnosis of type 1 diabetes, between 20% and 67% of children and adolescents present with diabetic ketoacidosis (DKA) requiring hospitalisation, and one-third of these require intensive care. Type 1 diabetes can be detected in early stages, prior to the insulin-requiring clinical diagnosis, through screening for islet autoantibodies (IAbs). Identifying individuals with early-stage type 1 diabetes, combined with monitoring of and education on disease progression, prevents DKA and results in a milder clinical onset.
This allows for timely insulin initiation in outpatient settings and improved long-term glucose management. Early diagnosis also enables access to novel disease-modifying therapies that can delay the clinical onset of diabetes. In this international consensus, we provide guidance on the principles and practice of implementing general population screening for IAbs to diagnose early-stage type 1 diabetes.
We also outline the minimum requirements for establishing effective population screening programmes to diagnose early-stage type 1 diabetes through IAb detection.
This consensus statement has been endorsed by the following professional associations: Advanced Technologies & Treatments for Diabetes (ATTD); Association of Diabetes Care and Education Specialists (ADCES); Association Belge Du Diabète; Associazione Medici Diabetologi (AMD); Australian Diabetes Society (ADS); Belgian Diabetes Liga; Breakthrough T1D; Czech Diabetes Society (ČDS); EASD; Finnish Diabetes Association (FDS); Fondazione Italiana Diabete (FID); International Diabetes Federation (IDF)-Europe; International Society of Paediatric and Adolescent Diabetes (ISPAD); Paediatric Endocrinology Nursing Society (PENS); Polish Diabetes Society; Portuguese Diabetes Association (APDP); Sociedade Portuguesa de Diabetologia (SPD); Società Italiana di Diabetologia (SID); Société Francophone du Diabète (SFD) and Type 1 Diabetes Exchange (T1D Exchange).
From the article
Conclusions
Detection of type 1 diabetes can now be achieved in its early stages, when autoimmunity is present but sufficient functional beta cell mass is still available to prevent frank hyperglycaemia.
Evidence from research in families already affected by type 1 diabetes and in children and adolescents at increased genetic risk and emerging studies in the general population demonstrate that detection of early-stage type 1 diabetes can be achieved effectively through IAb testing, resulting in improved outcomes including the reduction in frequency of DKA at clinical presentation with stage 3 type 1 diabetes.
Whereas opportunistic screening for the presence of IAbs can be performed at any age, we propose a structured pathway of screening for IAbs in childhood, with screening initiated at age 2–4 years and rescreening of those who screened negative during childhood, at the times when other preventive services are also being offered (i.e. at age 6–8 years and 10–15 years).
This consensus guidance will need to be translated into practice according to the prevailing healthcare system (and patient preference) in different national/regional settings. Adaptation of healthcare systems is recommended, to embed this screening in the established routines of primary care settings (e.g. linked to vaccination visits and well-baby examinations).
It should be clear that general population IAb screening initiatives should only roll out when healthcare services are fully prepared to implement the full screening pathway, including education and metabolic monitoring of those detected with early-stage type 1 diabetes. Combined with the arrival of disease-modifying therapies, this strategy should open the way to the delay and eventual prevention of clinical stage 3 type 1 diabetes.
Läs hela artikeln
International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabete
https://link.springer.com/article/10.1007/s00125-026-06841-z
Nyhetsinfo
www red DiabetologNytt